Please use this identifier to cite or link to this item:
Title: Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study
Author: Ibáñez Sanz, Gemma
Díez Villanueva, Anna
Vilorio-Marqués, Laura
Gracia-Lavedan, Esther
Aragonès Sanz, Núria
Olmedo Requena, Rocío
Llorca Díaz, Javier
Vidán, Juana
Amiano, Pilar
Nos, Pilar
Fernández Tardón, Guillermo
Rada, Ricardo
Chirlaque, María Dolores
Guinó, Elisabet
Dávila Batista, Verónica
Castaño-Vinyals, Gemma
Pérez Gómez, Beatriz
Mirón-Pozo, Benito
Dierssen Sotos, Trinidad
Etxeberria, Jaione
Molinuevo, Amaia
Álvarez-Cuenllas, Begoña
Kogevinas, Manolis
Pollán, Marina
Moreno Aguado, Víctor
Keywords: Espanya
Càncer colorectal
Estudi de casos
Medicina preventiva
Colorectal cancer
Case studies
Preventive medicine
Issue Date: 1-Feb-2018
Publisher: Nature Publishing Group
Abstract: A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.
Note: Reproducció del document publicat a:
It is part of: Scientific Reports, 2018, vol. 8, num. 1, p. 2040
Related resource:
ISSN: 2045-2322
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
679248.pdf918.27 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons